Taysha Gene Therapies (TSHA) Other Non-Current Assets (2021 - 2026)

Taysha Gene Therapies (TSHA) has 6 years of Other Non-Current Assets data on file, last reported at $2.8 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets rose 6.31% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $2.8 million (up 6.31% YoY), and the FY2025 full-year result was $2.3 million, down 10.96% from the prior year.
• Other Non-Current Assets improved to $2.8 million in Q1 2026, from $2.3 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $2.8 million in Q1 2026 to a low of $304000.0 in Q4 2023.
• A 5-year average of $2.4 million and a median of $2.6 million in 2024 frame the typical range for Other Non-Current Assets.
• Across the five-year window, Other Non-Current Assets plunged 88.47% in 2023 and surged 755.26% in 2024, its largest moves.
• Tracing TSHA's Other Non-Current Assets over 5 years: stood at $2.6 million in 2022, then sank by 88.47% to $304000.0 in 2023, then surged by 755.26% to $2.6 million in 2024, then retreated by 10.96% to $2.3 million in 2025, then increased by 19.4% to $2.8 million in 2026.
• Business Quant data shows TSHA's Other Non-Current Assets at $2.8 million in Q1 2026, $2.3 million in Q4 2025, and $2.2 million in Q3 2025.